



## Design and synthesis of indole derivatives of adenophostin A. A entry into subtype-selective IP<sub>3</sub> receptor ligands

Tetsuya Mochizuki<sup>a</sup>, Akihiko Tanimura<sup>b</sup>, Akihiro Nezu<sup>b</sup>, Mika Ito<sup>c</sup>, Hiroshi Abe<sup>c</sup>, Yoshihiro Ito<sup>c</sup>, Mitsuhiro Arisawa<sup>a</sup>, Satoshi Shuto<sup>a,\*</sup>

<sup>a</sup> Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan

<sup>b</sup> School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu 061-0293, Japan

<sup>c</sup> RIKEN, Advanced Science Institute, 2-1, Hirosawa, Wako, Saitama 351-0198, Japan

### ARTICLE INFO

#### Article history:

Received 30 October 2009

Revised 9 December 2009

Accepted 10 December 2009

Available online 16 December 2009

### ABSTRACT

Indole derivatives **3a** and **3b** of adenophostin A (**2**) in which the adenine of **2** was replaced with indole or 4-fluoroindole was designed as potential inositol trisphosphate receptor ligands. These target compounds were successfully synthesized from the key disaccharide unit **6**. Biological evaluation showed that **3b** selectively activates IP<sub>3</sub>R1, a subtype of IP<sub>3</sub> receptors.

© 2009 Elsevier Ltd. All rights reserved.

Adenophostin A (Fig. 1, **2**), isolated from *Penicillium brevicompactum*,<sup>1</sup> is a very potent *myo*-inositol 1,4,5-trisphosphate (IP<sub>3</sub>, **1**) receptor agonist, which is 10–100 times more potent than the endogenous ligand IP<sub>3</sub> in stimulating Ca<sup>2+</sup> release and in binding to IP<sub>3</sub> receptors.<sup>1b,1c</sup> Due to the high potency, its total synthesis<sup>2</sup> and also structure–activity relationship studies<sup>3,4</sup> have been extensively investigated. These studies have demonstrated that the adenine or the corresponding aromatic ring at the 1'β-position is essential for the high potency as an IP<sub>3</sub> receptor ligand.<sup>3,4</sup>

As a second messenger, IP<sub>3</sub> functions generally in many organs,<sup>5</sup> and at least three types of IP<sub>3</sub> receptor subtypes, those are, IP<sub>3</sub>R1, IP<sub>3</sub>R2, and IP<sub>3</sub>R3, are known.<sup>5b</sup> IP<sub>3</sub> receptor ligand, which is selectively active to one of the receptor subtypes, can be effectively used as a biological tool for investigating cellular signal transduction via IP<sub>3</sub>. However, none of the subtype-selective IP<sub>3</sub> receptor ligands

have been known so far. Thus, we focused our attention on the development of adenophostin analogs with IP<sub>3</sub> receptor subtype selectivity.

Recently, Potter and co-workers investigated the binding mode of **2** to the IP<sub>3</sub> receptor by molecular modeling using the X-ray crystal structure of IP<sub>3</sub>R1-binding core to suggest that the adenine of adenophostin A seems to associate with the guanidium side chain of Arg504 via a cation–π interaction in the binding pocket of IP<sub>3</sub>R1.<sup>3d</sup> Based on these modeling results, we designed an indole derivative **3a** of adenophostin A in which the adenine of adenophostin A is replaced by indole, as shown in Figure 1. The shape of indole is similar to that of adenine as a 5/6-fused aromatic ring system, and it has efficient electron-donating feature,<sup>6</sup> which might be suitable for the cation–π interaction speculated by the modeling. In addition, the electron-donating potency of the indole





Figure 1. IP<sub>3</sub> (**1**), adenophostin A (**2**), and the target indole derivatives **3a** and **3b**.

\* Corresponding author. Tel.: +81 11 706 3769; fax: +81 11 706 3769.

E-mail address: [shu@pharm.hokudai.ac.jp](mailto:shu@pharm.hokudai.ac.jp) (S. Shuto).



**Figure 2.** The optimized structures (**Ia** and **IIa**) and their electrostatic potential surfaces (**Ib** and **IIb**) of the model compounds **I** and **II** by DFT calculation.

ring may be controlled by introducing an electron-donating substituent or electron-withdrawing substituent.

Based on these findings and considerations, we also designed another indole derivative **3b** in which an electron-withdrawing fluoro group is substituted at the indole 4-position. We thought that if the cation– $\pi$  interaction is indeed important for the binding of adenophostin A to the receptor, affinity for the receptor might be changed depending on the electron-donating feature or electron-withdrawing feature of the substituent introduced at the indole moiety.

To understand the electronic properties of indole derivatives, quantum chemical calculation was carried out using 1-methylindole (**I**) and 4-fluoro-1-methylindole (**II**) as model compounds (Fig. 2).<sup>7</sup> The model compounds **I** and **II** were fully optimized based on density functional theory (DFT) giving the stable structures **Ia** and **IIa**, respectively. Electrostatic potential surface of the optimized structures **Ia** and **IIa** showed that 1-methylindole is electron-richer at the center of the aromatic ring than the corresponding 4-fluoro derivative, which is shown as **Ib** and **IIb**, respectively, in Figure 2. Furthermore, ionization energies of **Ia** and **IIa** were calculated at 7.0725 eV and 7.1424 eV, respectively. These calculation data indicated that 1-carbon-substituted indole is more electron-donating than the corresponding 4-fluoro congener, as we expected.

As shown in Scheme 1, we planned to synthesize the target compounds **3a** and **3b** via the  $\alpha$ -disaccharide **6**, which can be provided by the  $\alpha$ -selective glycosidation with a sulfoxide donor **4** and an acceptor **5**.<sup>4f</sup> The  $\alpha$ -disaccharide **6** has been used previously as an effective synthetic intermediate for synthesizing various derivatives of adenophostin A.<sup>4f</sup>

Synthesis of the target compound **3a** from **6** was accomplished as summarized in Scheme 2. After the removal of the 5-*O*-TBS group of **6**, the 5-hydroxyl was re-protected with an allyl group<sup>8</sup> to give **7**. Acidic removal of the ketal-protecting groups of **7**

followed by acetylation of the resulting free hydroxyls afforded the 1,2,3',4'-tetra-*O*-acetate **8**.


Indole nucleosides have been synthesized via glycosidation with indoline as a glycosyl acceptor and subsequent oxidative aromatization of indoline ring into indole ring.<sup>9</sup> Thus, using the tetra-*O*-acetate **8** as a glycosyl donor, when a solution of **8** and indoline (3 equiv) was heated in AcOH/EtOH (1:10) under reflux, the  $\beta$ -selective glycosidation occurred to give glycosidation product **9a**. Subsequent oxidative treatment of **9a** with MnO<sub>2</sub> in toluene yielded the desired  $\beta$ -indole nucleoside derivative **10a**<sup>10</sup> in 69% yield from **8**.

The 5'-*O*-allyl-protecting group was replaced with a TBS group at this stage.<sup>11</sup> Thus, long time heating of **10a** with (PPh<sub>3</sub>)<sub>3</sub>RhCl in toluene/EtOH under reflux and subsequent treatment of the resulting product with TBSCl/DMAP in pyridine gave the 5'-*O*-silyl ether **12a**. The three *O*-acetyl groups of **12a** were removed simultaneously with NaOMe/MeOH to give **13a**. The phosphate units were introduced into the 2'-, 3'-, and 4'-hydroxyls using the phosphoramidite method with *o*-xylene *N,N*-diethylphosphoramidite (XEPA).<sup>12</sup> Thus, **13a** was treated with XEPA in the presence of tetrazole as a promoter in CH<sub>2</sub>Cl<sub>2</sub>, followed by oxidation with *m*-CPBA to form the desired 2',3',4'-trisphosphate derivative **14a** in 97% yield. After the removal of the 5'-*O*-TBS group with TBAF/THF, the protecting groups of the phosphate moieties were finally removed under hydrogen atom transfer conditions with Pd(OH)<sub>2</sub> and cyclohexene in MeOH to furnish the target trisphosphate **3a** as a sodium salt, after treatment with ion-exchange resin.


Another target compound **3b** was synthesized by employing 4-fluoroindoline as an acceptor instead of indoline in the glycosidation step with the donor **8**, as shown in Scheme 2.

We have previously developed a method for the identification of ligands of IP<sub>3</sub>Rs using fluorescent biosensors,<sup>13,14</sup> and established subtype-specific IP<sub>3</sub> biosensors LIBRAvI and LIBRAvII for investigating binding affinity of IP<sub>3</sub> receptor ligands for IP<sub>3</sub>R1 and IP<sub>3</sub>R2, respectively.<sup>15</sup> Thus, the binding abilities of adenophostin A and the target compounds **3a** and **3b** were examined with these biosensors. Figure 3 indicates the increase in emission ratios of LIBRAvI and LIBRAvII with a same concentration (1  $\mu$ M) of these compounds. Effect of adenophostin A, **3a**, and **3b** on LIBRAvI was ~80%, ~40%, and ~35% of the maximal response, respectively. These results indicate that the potency of adenophostin A for the activation of IP<sub>3</sub>R1 is higher than that of compounds **3a** and **3b**. Although similar effects of adenophostin A and **3a** were observed on the emission ratio of LIBRAvII compared to those on LIBRAvI, the effect of target compounds **3b** on LIBRAvII was significantly small. Thus, their selectivity index (LIBRAvI/LIBRAvII) is 0.97 for adenophostin A, 1.1 for **3a**, and 8.4 for **3b**, respectively. These results indicate that 4-fluoroindole derivative **3b** has a higher selectivity for IP<sub>3</sub>R1 over IP<sub>3</sub>R2. To our knowledge, this kind of subtype-selective IP<sub>3</sub> receptor ligands has not been reported so far.


These results suggest that the indole ring in **3b** might not effectively work for the expected cation– $\pi$  interaction in its binding to the receptor. However, significantly weak binding of **3b** to the IP<sub>3</sub>R2 compared with that to the IP<sub>3</sub>R1 suggested that the subtype



**Scheme 1.**



**Scheme 2.** Reagents and conditions: (a) (1) TBAF, THF, rt; (2) CH<sub>2</sub>=CHCH<sub>2</sub>Br, Ca(OH)<sub>2</sub>, CaO, DMF, rt, 97%; (b) (1) 90% aq TFA, rt; (2) Ac<sub>2</sub>O, DMAP, Et<sub>3</sub>N, MeCN, rt, 77%; (c) indoline, AcOH, EtOH, reflux; (d) MnO<sub>2</sub>, toluene, rt, 69% (**10a**) from **8**, 77% (**10b**) from **8**; (e) (PPH<sub>3</sub>)<sub>3</sub>RhCl, toluene/EtOH, reflux, 68% (**11a**), 72% (**11b**); (f) TBSCl, DMAP, pyridine, rt, 64% (**12a**), 79% (**12b**); (g) NaOMe, MeOH, rt, quant (**13a**), quant (**13b**); (h) XEPA, tetrazole, CH<sub>2</sub>Cl<sub>2</sub>, -40 °C to rt, then *m*-CPBA, -40 °C, 97% (**14a**), 71% (**14b**); (i) (1) TBAF, THF, rt; (2) Pd(OH)<sub>2</sub>, cyclohexene, MeOH, reflux, 97% (**3a**), 97% (**3b**).



**Figure 3.** Binding affinities of adenophostin A (**2**) and its indole derivatives **3a** and **3b** for LIBRAVI and LIBRAVII. Effects of compounds on the emission ratio (480/535 nm) of LIBRAVI and LIBRAVII are expressed as % of maximal response. The maximal response was determined by the application of 30 μM IP<sub>3</sub> at the end of each experiment.

selectivity may be manipulated by changing the substituent at the indole 4-position in indole derivatives of adenophostin A.

In conclusion, the indole derivatives **3a** and **3b** designed as a novel IP<sub>3</sub> receptor ligands were successfully synthesized from the key disaccharide unit **6**. While binding affinities of **3a** and **3b** for IP<sub>3</sub>R1 and IP<sub>3</sub>R2 are weaker than adenophostin A, the 4-fluoroindole derivative **3b** was shown to be an IP<sub>3</sub>R1-selective ligand. Therefore, **3a** may be an effective lead for developing subtype-selective IP<sub>3</sub> receptor ligands, which can be useful biological tools.

## References and notes

- (a) Takahashi, M.; Kagasaki, T.; Hosoya, T.; Takahashi, S. *J. Antibiot.* **1993**, *46*, 1643–1647; (b) Takahashi, M.; Tanzawa, K.; Takahashi, S. *J. Biol. Chem.* **1994**, *269*, 369–372; (c) Hirota, J.; Michikawa, T.; Miyawaki, A.; Takahashi, M.; Tanzawa, K.; Okura, I.; Furuichi, T.; Mikoshiba, K. *FEBS Lett.* **1995**, *368*, 248–252.
- Total synthesis of adenophostin A: (a) Hotoda, H.; Takahashi, M.; Tanzawa, K.; Takahashi, S.; Kaneko, M. *Tetrahedron Lett.* **1995**, *36*, 5037–5040; (b) van Straten, N. C. R.; van der Marel, G. A.; van Boom, J. H. *Tetrahedron* **1997**, *53*, 6509–6522; (c) Marwood, R. D.; Correa, V.; Taylor, C. W.; Potter, B. V. L. *Tetrahedron: Asymmetry* **2000**, *11*, 397–403.
- Synthesis of adenophostin A analogs see: (a) de Kort, M.; Regenbogen, A. D.; Overkleef, H. S.; Challis, J.; Iwata, Y.; Miyamoto, S.; van der Marel, G. A.; van Boom, J. *Tetrahedron* **2000**, *56*, 5915–5928, and references therein; (b) Chretien, F.; Moitessier, N.; Roussel, F.; Mauger, J. P.; Chapleur, Y. *Curr. Org. Chem.* **2000**, *4*, 513–534; (c) Roussel, F.; Moitessier, N.; Hilly, M.; Chretien, F.; Mauger, J.-P.; Chapleur, Y. *Bioorg. Med. Chem.* **2002**, *10*, 759–768; (d) Rosenberg, H. J.; Riley, A. M.; Laude, A. J.; Taylor, C. W.; Potter, B. V. L. *J. Med. Chem.* **2003**, *46*, 4860–4871; (e) Rossi, A. M.; Riley, A. M.; Tovey, S. C.; Rahman, T.; Dellis, O.; Taylor, E. J.; Veresov, V. G.; Potter, B. V.; Taylor, C. W. *Nat. Chem. Biol.* **2009**, *5*, 631–639, and references therein.
- (a) Shuto, S.; Tatani, K.; Ueno, Y.; Matsuda, A. *J. Org. Chem.* **1998**, *63*, 8815–8824; (b) Abe, H.; Shuto, S.; Matsuda, A. *J. Org. Chem.* **2000**, *65*, 4315–4325; (c) Shuto, S.; Yahiro, Y.; Ichikawa, S.; Matsuda, A. *J. Org. Chem.* **2000**, *65*, 5547–5557; (d) Mochizuki, T.; Kondo, Y.; Abe, H.; Taylor, C. W.; Potter, B. V. L.; Matsuda, A.; Shuto, S. *Org. Lett.* **2006**, *8*, 1455–1458; (e) Terauchi, M.; Abe, H.; Tovey, S. C.; Dedos, S. G.; Taylor, C. W.; Paul, M.; Trusselle, M.; Potter, B. V. L.; Matsuda, A.; Shuto, S. *J. Med. Chem.* **2006**, *49*, 1900–1909; (f) Mochizuki, T.; Kondo, Y.; Abe, H.; Tovey, S. C.; Dedos, S. G.; Taylor, C. W.; Paul, M.; Potter, B. V. L.; Matsuda, A.; Shuto, S. *J. Med. Chem.* **2006**, *49*, 5750–5758, and references therein.
- (a) Berridge, M. J. *Nature (London)* **1993**, *361*, 315–325; (b) Joseph, S. K. *Cell. Signalling* **1996**, *8*, 1–7.
- (a) Mecozzi, S.; West, A. P.; Dougherty, D. A. *J. Am. Chem. Soc.* **1996**, *118*, 2307–2308; (b) Yorita, H.; Otomo, K.; Hiramatsu, H.; Toyama, A.; Miura, T.; Takeuchi, H. *J. Am. Chem. Soc.* **1996**, *118*, 2307–2308; (c) Inoue, Y.; Sugio, S.; Andzelm, J.; Makamura, N. *J. Phys. Chem. A* **1998**, *102*, 646–648.
- The preoptimized geometries by HF/3-21G\* were taken to be the input geometries for final optimization by B3LYP/6-31G\*. Single point energies and all electronic properties were calculated by B3LYP/6-31G\*.
- Preliminary experiments suggested that in the glycosidation of α-disaccharide donors at the β-position of the ribose moiety with indoline as an acceptor, a bulky protecting group, such as TBS group, at the 5-primary hydroxyl of the donor might prevent the glycosidation to proceed.
- Preobrazhetskaya, M. N.; Vigdorich, M. M.; Suvorov *Tetrahedron* **1967**, *23*, 4653–4660.
- The anomeric β-configuration was confirmed from an NOE correlation between H-2 of the indole moiety and H-2' of the ribose moiety.
- When deprotection of the 5'-O-allyl group was examined after the introduction of the *o*-xylene phosphate units at the 2', 3', and 4'-hydroxyls, it was unsuccessful.
- Watanabe, Y.; Komoda, Y.; Ebisuya, K.; Ozaki, S. *Tetrahedron Lett.* **1990**, *31*, 255–256.
- Nezu, A.; Tanimura, A.; Morita, T.; Shitara, A.; Tojyo, Y. *Biochim. Biophys. Acta Gen. Subj.* **2006**, *1760*, 1274–1280.
- Zhang, L.; Huang, W.; Tanimura, A.; Morita, T.; Harihar, S.; De Wald, D. B.; Prestwich, G. D. *Chem. Med. Chem.* **2007**, *2*, 1281–1289.
- Tanimura, A.; Morita, T.; Nezu, A.; Shitara, A.; Hashimoto, N.; Tojyo, Y. *J. Biol. Chem.* **2009**, *284*, 8910–8917.